Funders › CA › Institute for Follicular Lymphoma Innovation › 2024
Grants paid by Institute for Follicular Lymphoma Innovation, tax year 2024
EIN 88-0639274 · Diamond Bar, CA · Form 990-PF, Part XV · NTEE T20
In tax year 2024, Institute for Follicular Lymphoma Innovation (EIN 88-0639274) reported 10 grants paid totaling $9,045,427. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2024
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Lymphoma Research Foundation New York, NY | B | $3,282,650 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Lysarc Pierre Benite | U | $2,336,450 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Lysarc Pierre Benite | U | $2,034,383 | approved, future | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | The Leukemia & Lymphoma Society Inc Rye Brook, NY | U | $1,211,957 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Beckman Research Institute - City of Hope Duarte, CA | U | $1,151,166 | approved, future | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Washington University St Louis, MO | B | $700,961 | approved, future | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Washington University St Louis, MO | B | $700,960 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Beckman Research Institute - City of Hope Duarte, CA | U | $467,783 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Cure (llsflfifli) Rye Brook, NY | U | $447,333 | approved, future | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Inserm Paris, PARIS CEDEX 13 | U | $311,117 | approved, future | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Lymphoma Research Foundation New York, NY | B | $284,350 | approved, future | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | UCLA Los Angeles, CA | D | $275,000 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | The Leukemia & Lymphoma Society Inc Rye Brook, NY | U | $250,000 | approved, future | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | The Francis Crick Institute Limited London | U | $249,969 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Inserm Paris, PARIS CEDEX 13 | U | $239,133 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Cure (llsflfifli) Rye Brook, NY | U | $223,667 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | The Francis Crick Institute Limited London | U | $199,975 | approved, future | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
| 2024 | Rafl Program (ifli & Lls Collaboration) Rye Brook, NY | U | $57,858 | paid | FOR RESEARCH TOWARDS FINDING A CURE FOR FOLLICULAR LYMPHOMA | 202523219349108817 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.